This Medudy Master Class Series is a video tutorial for physicians on the topic "Therapy of triple-negative breast cancer (TNBC) in stage II and III with a focus on the role of immunotherapy", presented by Prof. Sherko Kümmel
This episode takes a detailed look at the current treatment standards and key issues at this early stage of the disease. The roles of substances such as olaparib, capecitabine and carboplatin in neoadjuvant therapy are highlighted. A particular focus will be on pembrolizumab and the study results that demonstrate the potentially greatest benefit of additional immunotherapy in TNBC.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was created with the kind support of Gilead Sciences and MSD.
At the end of this training you will know:
- the central issues and current treatment standards for stage II and III triple-negative breast cancer (TNBC)
- the efficacy and targeted use of active substances such as olaparib, capecitabine (for non-pCR) and carboplatin
- the importance of neoadjuvant chemotherapy for assessing tumor response and the resulting options for de-escalation.
- the current evidence and the role of pembrolizumab and other immune checkpoint inhibitors in increasing pathological complete response (pCR)
